EACR conference « Cellular Bases for Patient Response to Cancer Therapies »
SB-PEPTIDE is pleased to participate and exhibit at the EACR conference on cellular bases for patient response to cancer therapies that will be held in Lyon from November 14th to 16th 2023.
Meet our delegate at Booth #1 !
SB-PEPTIDE co-founder & CCO
After a Master's degree in Biothechnology and management, Aurélien has operated as business developer at the University of Grenoble to promote laboratory innovations. During this period, he worked actively on the development of a peptide drug discovery activity which has been incorporated in 2013 under the name of Smartox Biotechnology. Co-founded with 2 other associates, Aurélien led the business development strategy. In 2016, Smartox launched SB-PEPTIDE, a subsidiary devoted to peptide manufacturing. Aurélien manages the global commercial operations and strategy.
Feel free to connect!
Cellular Bases for Patient Response to Cancer Therapies
This conference will delve into the most cutting-edge studies that have revealed novel molecular pathways involved in response to anticancer therapy.
Discover the latest breakthroughs in cancer research! Instead of relying on outdated cell line-based preclinical tests, recent studies have taken a bold new approach by testing conventional chemotherapy and hormone therapy directly on in vivo models and patients. These innovative methods have led to the discovery of previously unknown modes of action and cellular effects that have the potential to revolutionize cancer treatment.
Get ready to hear from a panel of expert speakers who are at the forefront of this exciting research. They will share their insights and visions on how these game-changing discoveries can be utilized to rethink cancer therapies and ultimately improve patient outcomes. Don’t miss out on this opportunity to learn about the cutting-edge science that is shaping the future of cancer treatment !
Visit the EACR conference website !
Custom peptide synthesis
Peptides library synthesis